PRTC vs. GNS, ONT, ERGO, SLN, OXB, HZD, FARN, VRP, ARIX, and CIR
Should you be buying PureTech Health stock or one of its competitors? The main competitors of PureTech Health include Genus (GNS), Oxford Nanopore Technologies (ONT), Ergomed (ERGO), Silence Therapeutics (SLN), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), and Circassia Group (CIR). These companies are all part of the "biotechnology" industry.
PureTech Health vs. Its Competitors
PureTech Health (LON:PRTC) and Genus (LON:GNS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.
79.9% of PureTech Health shares are held by institutional investors. Comparatively, 77.8% of Genus shares are held by institutional investors. 15.9% of PureTech Health shares are held by insiders. Comparatively, 0.8% of Genus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
PureTech Health currently has a consensus price target of GBX 455, suggesting a potential upside of 264.23%. Genus has a consensus price target of GBX 2,150, suggesting a potential upside of 7.10%. Given PureTech Health's higher possible upside, equities analysts plainly believe PureTech Health is more favorable than Genus.
Genus has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.
In the previous week, PureTech Health and PureTech Health both had 1 articles in the media. PureTech Health's average media sentiment score of 1.47 beat Genus' score of 0.00 indicating that PureTech Health is being referred to more favorably in the media.
Genus has a net margin of 1.18% compared to PureTech Health's net margin of -17,620.94%. Genus' return on equity of 1.41% beat PureTech Health's return on equity.
PureTech Health has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Comparatively, Genus has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500.
Summary
Genus beats PureTech Health on 8 of the 14 factors compared between the two stocks.
Get PureTech Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PureTech Health Competitors List
Related Companies and Tools
This page (LON:PRTC) was last updated on 7/1/2025 by MarketBeat.com Staff
